title: Plasma collagen-binding vitronectin activated by heparin and dextran sulfate in chronic liver disease.
abstract: Plasma collagen-binding vitronectin was assayed in 62 patients with chronic liver disease and 14 healthy control subjects. It was measured by an enzyme immunoassay using type I collagen and monoclonal antibody to vitronectin before and after treatment with heparin or dextran sulfate in vitro. The pretreatment level of plasma collagen-binding vitronectin (mean +/- S.E.M.) was 5.5 +/- 0.5 micrograms/ml in the controls, 8.2 +/- 0.3 micrograms/ml in chronic persistent hepatitis, 8.3 +/- 0.7 micrograms/ml in chronic active hepatitis, 7.9 +/- 0.7 micrograms/ml in liver cirrhosis, and 8.2 +/- 0.5 micrograms/ml in hepatocellular carcinoma with cirrhosis. After treatment with heparin, the percent collagen-binding vitronectin to total vitronectin was 20.6 +/- 2.0% in the controls, 24.7 +/- 4.1% in chronic persistent hepatitis, 28.6 +/- 2.5% in chronic active hepatitis, 42.6 +/- 4.5% in liver cirrhosis, and 31.8 +/- 2.3% in hepatocellular carcinoma. All percents were significantly increased compared to the pretreatment percent. The same pattern was also found after dextran sulfate treatment. Compared to that in the pretreatment state, the collagen-binding vitronectin after these treatments was more closely correlated with the serum levels of 7S collagen and hyaluronic acid. These results suggest that the collagen-binding activity of vitronectin may play an important role in the progression of liver disease and/or fibrosis through its activation with some glycosaminoglycans.
authors.affiliation: Second Department of Internal Medicine, Faculty of Medicine Tottori University, Yonago, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: J
authors.initials: J
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Kawasaki
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D003094:Collagen / Q000097:blood*; D016264:Dextran Sulfate / Q000627:therapeutic use*; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D007124:Immunoenzyme Techniques; D008107:Liver Diseases / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D011393:Procollagen-Proline Dioxygenase / Q000097:blood; D019096:Vitronectin / Q000097:blood*
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; D011347:Procollagen; D019096:Vitronectin; C041876:procollagen Type III-N-terminal peptide; D006820:Hyaluronic Acid; D006493:Heparin; D003094:Collagen; D016264:Dextran Sulfate; D011393:Procollagen-Proline Dioxygenase